Cipla shares jumped nearly 11% across two sessions after multiple brokerages upgraded their outlook, even though Q4 profit fell 55% year on year. The rally pushed the stock to an intraday high of Rs 1,432.10 as investors shifted attention from near-term earnings pressure to longer-term growth prospects highlighted by analysts.
Cipla Ltd reported a steep 55% year-on-year fall in consolidated net profit for Q4, dropping to Rs 555 crore from Rs 1,222 crore a year earlier. Despite the decline, the board recommended a final dividend of Rs 13 per share for the fiscal year ending March 2026, signaling continued shareholder payout plans.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Cohance Lifesciences shares surged 20% on Monday after appointing former Cipla CEO Umang Vohra as Executive Chairman and Group CEO. The company expects his leadership to push transformation, expand operations, and deepen global partnerships as it moves into a new growth phase. Investors reacted sharply to the change at the top.
Cipla is moving forward with the sale of Afrezza, an insulin patients inhale from the mouth, aiming to offer a painless alternative to injectable insulin. The big question is whether this inhaled option can gain traction against entrenched global players and established injection-based routines in diabetes care.
Cipla has received final approval from the USFDA for its generic albuterol sulfate inhalation aerosol, a key medicine used for respiratory conditions. The clearance strengthens Cipla’s US portfolio and provides a therapeutic equivalent to a widely used branded drug, underlining its momentum in the respiratory segment.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
